Schott Pharma stock slips as Q3 revenue tops $300 million
Published on 08/25/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Schott Pharma stock slipped 0.4% to EUR 22.80 in XETRA trade on August 25, 2026, with 978 shares changing hands and the session low also at EUR 22.80. The move follows the company's latest quarter, reported on August 12, 2026, which showed EUR 281.76 million in revenue and EPS of EUR 0.26.
Quarterly numbers
The same report showed revenue up 9.87% from EUR 256.46 million a year earlier, while EPS eased from EUR 0.30 in the prior-year quarter. That makes the growth-and-margin mix the main question for investors, not just the day-to-day tape.
Trading range
The stock's 52-week range spans from EUR 12.62 on March 23, 2026 to EUR 24.00 on August 27, 2025, and today's price sits much closer to the top of that band than the bottom. A move of 5.26% from here would print a fresh 52-week high.
Product lens
Schott Pharma's glass and polymer packaging business remains tied to injectable medicines, where container quality and delivery volumes shape reported sales more than headline branding. In the latest quarter, the company paired EUR 281.76 million in sales with a year-over-year revenue gain of 9.87%, a combination that points to steady demand rather than a one-off spike.
Price check
Schott Pharma shares traded at EUR 22.80 on August 25, 2026, after a 0.4% decline from the prior level. The session's opening print was EUR 22.95.
Company details
Company: Schott Pharma SE<br>ISIN: DE000A3ENQ51<br>Ticker: S7P<br>Exchange: XETRA<br>Price (as of August 25, 2026): EUR 22.80<br>Market cap: not included in the provided market snapshot<br>Sector / Industry: Health Care / Pharmaceuticals<br>Index membership: SDAX<br>Next earnings date: December 10, 2026
